IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03734783|
Recruitment Status : Completed
First Posted : November 8, 2018
Last Update Posted : November 18, 2019
|Condition or disease|
|Chronic Hepatitis b|
Regulatory B cells (Bregs) are involved in the immune tolerance process through multiple pathways and Bregs are involved in the process of chronic HBV infection.
Here the investigators intended to investigate the regulating role and the mechanism of CD19+ IL-35+ cells on host T cell immune during chronic HBV infection by using in vitro cell sorting, B cell differentiation induction, Transwell cell co-culture system and other methods.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||55 participants|
|Target Follow-Up Duration:||1 Day|
|Official Title:||Regulate Effect of Il-35 Secreting Breg Cells on Tcells and on Diseases Progression in Patients With CHB|
|Actual Study Start Date :||July 1, 2017|
|Actual Primary Completion Date :||November 15, 2019|
|Actual Study Completion Date :||November 15, 2019|
HBsAg positive more than 6 months
- IL-35+Bregs level [ Time Frame: ENROLLED DAY ]IL-35 secreting regulatory B cells level in patients with CHB
- IL-35+Bregs regulatory effect [ Time Frame: enrolled day ]regulatory effect of IL-35+Bregs on T cell immune
- IL-35+Bregs phenotype [ Time Frame: enrolled day ]the main phenotype of IL-35 secreting Bregs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03734783
|Shanghai, China, 200433|